Notice regarding the status of share repurchases
Filed with TSE · · 1 page · English
Otsuka Holdings Co., Ltd. on 6ix
Later from Otsuka
- Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT Preserved Kidney Function Over 12 Months in IgA Nephropathy
- Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results for VOYXACT in IgAN
- Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
- Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2026
- Consolidated Financial Results for the Six-Month Period Ended June 30, 2026 [IFRS]
Follow Otsuka into a list and get an email when it puts out news.
Follow Otsuka